Evaluation of the JRI Cemented Hip Hemiarthroplasty: Mid-Term Results Including Patient-Reported Outcomes

Hemiarthroplasty is the primary treatment for displaced intracapsular hip fractures in frail patients. Implant selection is crucial to reduce reoperations, which carry a high complication risk. This study reports on reoperations, mortality, revisions, and patient-reported outcome measures (PROMs) following the use of the JRI (Joint Replacement Instrumentation Limited) Furlong Cemented Hemiarthroplasty prosthesis.

We undertook a retrospective cohort study at a major trauma centre in the United Kingdom. All intracapsular neck of femur patients aged over 60 who underwent cemented hip hemiarthroplasty with the JRI Furlong femoral stem over a 5 year period from January 2018 to December 2022 were included. The primary outcome measure was reoperation, including closed reduction of dislocation. Secondary outcome measures were dislocation specifically, revision, mortality and PROMs.

1183 patients in the study period (793 female, 390 male) with an average age of 84.3 were followed up to 6 years. For a subset of patients, PROMs were recorded at 4 months (n = 237) and 3 years (n = 215). The reoperation rate at 1 year was 1.13% (95% CI 0.64% to 1.99%), increasing to 1.62% (95% CI 0.95% to 2.75%) at 5 years. The 5-year revision rate was 0.68% (95% CI 0.39% to 1.55%); 5-year dislocation rate was 0.87% (95% CI 0.45% to 1.67%). Mean EQ5D utility score was 0.621 at 4 months and 0.603 at 3 years for those alive.

Our cohort shows low re-operation, revision and dislocation rates in the mid-term. We describe acceptable PROMS in the context of a frail population.